Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 64 clinical trials
featured
Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndrome (MDS)

  • 256 views
  • 08 Nov, 2020
  • 1 location
Allogeneic HSCT in MDS Patients Based on Risk According to R-IPSS

An "intention-to-treat" study to evaluate the impact of allogeneic HSCT with Total Marrow and Lymphoid irradiation (TMLI), followed by Treg/Tcon adoptive immunotherapy, on overall survival in patients affected by Myelodysplastic Syndrome (MDS), according to IPSS-R.

  • 0 views
  • 27 Mar, 2021
  • 1 location
HDM201 in Combination With MBG453 or Venetoclax in Patients With Acute Myeloid Leukemia (AML) or High-risk Myelodysplastic Syndrome (MDS)

This is a phase 1b, multi-arm, open-label study of HDM201 in combination with MBG453 or venetoclax in subjects with AML or high-risk MDS. For all subjects, TP53wt status must be

refractory acute myeloid leukemia (aml)
venetoclax
TP53
cell transplantation
induction chemotherapy
  • 51 views
  • 14 May, 2021
  • 10 locations
A Dose-finding Study of CC-90009 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-risk Myelodysplastic Syndromes

CC-90009-AML-001 is a phase 1, open-label, dose escalation and expansion, study in subjects with relapsed or refractory acute myeloid leukemia and relapsed or refractory high-risk

refractory acute myeloid leukemia (aml)
hydroxyurea
myelodysplastic syndromes
donor lymphocyte infusion
leukemia
  • 0 views
  • 25 Jul, 2021
  • 25 locations
Magrolimab + Azacitidine Versus Azacitidine + Placebo in Untreated Participants With Myelodysplastic Syndrome (MDS)

with intermediate/high/very high risk myelodysplastic syndrome (MDS) by Revised International Prognostic Scoring System (IPSS-R) as measured by complete remission (CR) and overall survival (OS).

remission
azacitidine
high risk myelodysplastic syndrome
  • 0 views
  • 23 Jul, 2021
  • 79 locations
Study of Efficacy and Safety of MBG453 in Combination With Azacitidine in Subjects With Intermediate High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R or Chronic Myelomonocytic Leukemia-2 (CMML-2)

or very high risk myelodysplastic syndrome (MDS) as per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2) who have an indication for treatment with azacitidine in first-line setting and are not

myelomonocytic leukemia
high risk myelodysplastic syndrome
azacitidine
leukemia
stem cell transplantation
  • 5 views
  • 25 Jul, 2021
  • 127 locations
A Trial of Treatments to Assess the Effects on Outcome of Adults With AML and MDS Undergoing Allogeneic SCT

patients with high risk disease. This study will evaluate new transplant strategies with the aim of improving the outcome of patients with AML and high risk MDS after stem cell transplantation

consolidation therapy
thiotepa
leukemia
hla-a
myeloid leukemia
  • 0 views
  • 24 Jan, 2021
  • 1 location
Trial to Test the Effects of Adding 1 of 2 New Treatment Agents to Commonly Used Chemotherapy Combinations

The AML18 Trial will evaluate several relevant therapeutic questions in Acute Myeloid Leukaemia (AML), as defined by the WHO, and High Risk Myelodysplastic Syndrome. The trial is primarily

mylotarg
high risk myelodysplastic syndrome
leukemia
cladribine
myeloid leukemia
  • 381 views
  • 23 Jan, 2021
  • 83 locations
Study to Assess Safety Tolerability Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological Malignancies

The purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary antitumor activity of AZD4573 in subjects with relapsed or refractory haematological malignancies.

cancer
hodgkin's disease
lymphoma
secondary aml
progressive disease
  • 98 views
  • 02 Jul, 2021
  • 23 locations
High Risk Myelodysplasia Treated by Azacytidine : Genetic and Epigenetic (MYRAGE)

, which prognosis is evaluated with International Prognosis Scoring System. High risk MDS present with high frequency of transformation into acute myeloid leukemia. Treatment of high risk MDS often is

  • 0 views
  • 23 Jan, 2021
  • 2 locations